@entity230 after the Kasai procedure for XXXX : the effect of age at Kasai portoenterostomy.

@entity1 @entity1087 @entity2876 @entity230 @entity617
UNASSIGNED: The use of adjuvant @entity230 following Kasai porteoenterostomy (KPE) for @entity2876 is controversial. The aim of this study was twofold: a systematic review of published literature and an update of the clinical Kings College Hospital series to look for evidence of an effect of age on the outcome in a group of BA @entity1 treated with high-dose @entity230 . This clinical study included @entity1 treated between January 2006 and June 2014 who underwent KPE by day 70 of life and who received high-dose @entity230 (oral @entity617 starting 5  mg/kg/day). They were subdivided into cohorts according to age at which KPE was performed. The outcome measured was clearance of @entity1087 (<20    mol/L) by 6  months and native liver survival. R  *  C   (2) analysis and log-rank tests were used, respectively, and P   <=  0.05 was regarded as significant. 104 @entity1 were included with a median age at KPE of 45 (range 12-70) days. 71/104 (67  %) cleared their @entity1087 by 6  months of age. Age-cohort analysis showed a trend (P  =  0.03) favouring early KPE (e.g. 100  % of 11 @entity1 operated on <30  days clearing their @entity1087 compared to 66  % of those operated on between 61 and 70  days). There was a significant native liver survival benefit for those operated on <45  days (5  year NLS estimate 69 versus 46  %; P  =  0.05). Clearance of @entity1087 is related to the age at KPE in @entity1 who receive high-dose @entity230 . Native liver survival appears to be improved as a result of this. This is the first study to show tangible longer-term benefit from high-dose @entity230 in @entity2876 .
